Canaccord Genuity reiterated their hold rating on shares of AngioDynamics, Inc. (NASDAQ:ANGO) in a report issued on Wednesday morning. The brokerage currently has a $16.50 price objective on the medical instruments supplier’s stock.
Other research analysts have also recently issued research reports about the company. Barclays PLC initiated coverage on AngioDynamics in a report on Wednesday, February 8th. They issued an equal weight rating and a $17.00 target price on the stock. Zacks Investment Research cut AngioDynamics from a hold rating to a sell rating in a report on Friday, March 10th. Cantor Fitzgerald reiterated a buy rating and issued a $20.00 target price on shares of AngioDynamics in a report on Thursday, March 30th. Finally, Craig Hallum set a $20.00 target price on AngioDynamics and gave the company a buy rating in a report on Saturday, April 1st. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. AngioDynamics presently has a consensus rating of Buy and a consensus price target of $18.58.
AngioDynamics (NASDAQ:ANGO) opened at 15.26 on Wednesday. The firm’s market cap is $561.26 million. AngioDynamics has a 52 week low of $12.25 and a 52 week high of $18.18. The stock has a 50 day moving average price of $15.60 and a 200 day moving average price of $16.42.
AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings data on Thursday, March 30th. The medical instruments supplier reported $0.19 EPS for the quarter, beating the Zacks’ consensus estimate of $0.15 by $0.04. The business had revenue of $85.60 million during the quarter, compared to the consensus estimate of $88.29 million. AngioDynamics had a positive return on equity of 4.87% and a negative net margin of 7.91%. The business’s revenue for the quarter was down 2.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.15 earnings per share. Equities research analysts expect that AngioDynamics will post $0.70 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This news story was published by Mideast Time and is the sole property of of Mideast Time. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://www.mideasttime.com/angiodynamics-ango-hold-rating-reiterated-at-canaccord-genuity/1754874.html.
In related news, major shareholder Avista Capital Partners Gp, Ll sold 2,350,000 shares of AngioDynamics stock in a transaction on Wednesday, April 12th. The stock was sold at an average price of $16.00, for a total value of $37,600,000.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 1.88% of the stock is currently owned by company insiders.
Hedge funds and other institutional investors have recently modified their holdings of the company. Swiss National Bank boosted its position in shares of AngioDynamics by 0.8% in the third quarter. Swiss National Bank now owns 49,300 shares of the medical instruments supplier’s stock worth $865,000 after buying an additional 400 shares in the last quarter. Americafirst Capital Management LLC bought a new position in shares of AngioDynamics during the third quarter worth approximately $1,815,000. BlackRock Fund Advisors boosted its position in shares of AngioDynamics by 14.2% in the third quarter. BlackRock Fund Advisors now owns 2,051,381 shares of the medical instruments supplier’s stock worth $35,981,000 after buying an additional 255,064 shares in the last quarter. Municipal Employees Retirement System of Michigan boosted its position in shares of AngioDynamics by 7.3% in the third quarter. Municipal Employees Retirement System of Michigan now owns 6,330 shares of the medical instruments supplier’s stock worth $111,000 after buying an additional 430 shares in the last quarter. Finally, State of Tennessee Treasury Department boosted its position in shares of AngioDynamics by 10.0% in the third quarter. State of Tennessee Treasury Department now owns 22,865 shares of the medical instruments supplier’s stock worth $401,000 after buying an additional 2,075 shares in the last quarter. Institutional investors own 79.52% of the company’s stock.
AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.
Receive News & Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.